ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1452

COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study

Clio Mavragani1, Athanasios-Dimitrios Bakasis2, Kyriaki Boki3, Athanasios Tzioufas4, Panayiotis Vlachoyiannopoulos1, Ioanna Stergiou5, Fotini Skopouli6 and Haralampos Moutsopoulos7, 1National and Kapodistrian University of Athens, Athens, Greece, 21 Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 33 Rheumatology Unit, Sismanoglio General Hospital, Athens, Greece, Athens, Greece, 4Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 5Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, 6Department of Nutrition and Clinical Dietetics, Harokopio University of Athens, Athens, Greece, 7Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Autoinflammatory diseases, Comorbidity, COVID-19, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

Session Type: Abstract Session

Session Time: 3:30PM-3:45PM

Background/Purpose: The impact of COVID-19 infection in patients with autoimmune/auto-inflammatory rheumatic diseases (AARD) under immunomodulatory treatment is not entirely clear and deeper knowledge is of paramount importance during the SARS-CoV-2 pandemic. Whether risk factors as in the general population or the immune dysregulation in the context of the underlying AARD per se and/or the immunomodulatory therapy used predispose to a more severe disease course and hospitalization, has to be elucidated.

Methods: In this observational study, demographic data, AARD related features and comorbidities, COVID-19 manifestations and outcome, as well as antibody responses to SARS-CoV-2 were recorded among 77 AARD patients infected by SARS-CoV-2. We next wished to identify risk factors for COVID-19 severity and subsequent hospitalization Analysis of data was performed using univariate and multivariate models.

Results: The majority of patients (68.8%) experienced a mild COVID-19 course. The predominant symptoms were upper respiratory tract symptoms (68.8%), fatigue (58.4%) and low grade fever (45.4%). One out of four patients required hospitalization (23.3%) and the mortality rate was 1.3%. Regarding COVID-19 severity, prior treatment with corticosteroids, mycophenolate mofetil or rituximab was more common in patients who developed a more serious disease course (60.0 vs 29.9%, p=0.003, 40.0 vs 7.5%, p=0.003, 10.0 vs 0.0%, p=0.009, respectively). Among COVID-19 related features, patients with shortness of breath and high-grade fever were more likely to get hospitalized (OR [95%]: 7.06 [1.36–36.57], 12.04 [2.96–48.86]), while anosmia was independently associated with lower hospitalization risk (OR [95%]: 0.09 [0.01–0.99]). When disease related features and comorbidities were considered in multivariate models, older age and lung disease in the context of the AARD were found to be independent predictive factors for hospitalization (OR [95%]: 1.09 [1.03–1.15] and 6.43 [1.11–37.19]).

Conclusion: Though the majority of AARD patients displayed a mild COVID-19 course, certain AARD related features and COVID-19 related manifestations should prompt alertness for the physician to identify patients with AARD at high risk for severe COVID-19 and need for hospitalization.


Disclosures: C. Mavragani, None; A. Bakasis, None; K. Boki, None; A. Tzioufas, None; P. Vlachoyiannopoulos, None; I. Stergiou, None; F. Skopouli, None; H. Moutsopoulos, None.

To cite this abstract in AMA style:

Mavragani C, Bakasis A, Boki K, Tzioufas A, Vlachoyiannopoulos P, Stergiou I, Skopouli F, Moutsopoulos H. COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/covid-19-infection-among-autoimmune-auto-inflammatory-rheumatic-disease-patients-data-from-an-observational-study/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/covid-19-infection-among-autoimmune-auto-inflammatory-rheumatic-disease-patients-data-from-an-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences